Quick Facts

• Therapeutic Domain: Bacterial Infections
• Key Areas of Use: Lungs, Urinary Tract, Ear, Throat
• Specific Conditions: Pharyngitis, Tonsillitis, Acute Bronchitis

Alcef-O is a medication utilized in the management of certain bacterial infections. It is considered appropriate when a health professional determines that an infection is caused by bacteria susceptible to its components.

The primary uses of this medicine include the treatment of various infections affecting the upper and lower respiratory tract, such as acute exacerbations of chronic bronchitis, tonsillitis, and pharyngitis (strep throat). It is also frequently prescribed to address infections of the ear (otitis media) and uncomplicated infections within the urinary tract. Additionally, this medicine is considered a therapeutic option for managing uncomplicated gonorrhea that affects the cervix or urethra.

All treatments with this medication are intended to help reduce the intensity of ongoing suffering by targeting the susceptible bacteria.

Who Can and Cannot Use Alcef-O?

This section outlines the official population eligibility and non-eligibility rules for Alcef-O (Cefixime) as documented by government regulatory bodies.

---

Absolute Contraindications (Cannot Use)

The medicine is strictly prohibited for patients with a documented allergy or severe hypersensitivity reaction to cefixime or any other cephalosporin antibiotic. Furthermore, a history of severe penicillin allergy imposes a major restriction due to the risk of cross-reactivity.

---

Populations Allowed and Restrictions

Population Group	Eligibility Status	Key Restriction/Condition
Adults and Children	Eligible	Must be six months of age or older (use is not established in infants below 6 months).
Severe Renal Impairment	Conditional	Use is restricted and requires close monitoring, as the drug's elimination is impaired.
Pregnancy/Lactation	Conditional	Use is restricted; advised only if the benefit is clearly determined to outweigh the potential risk.
Older Adults	Eligible	Renal function should be considered, as age-related decline may require a use adjustment.

Eligibility criteria are defined by health authorities and are not based on individual circumstances or medical advice.

Interactions with other medicines and products

Official regulatory information documents specific interaction patterns for the active ingredient Cefixime, with additional considerations if the product is a combination containing Ofloxacin.

Pharmacokinetic and Pharmacodynamic Interactions

The co-administration of Probenecid with Cefixime is officially documented to inhibit renal tubular secretion, which results in a reduction of Cefixime clearance and a consequential increase in its plasma concentration. When Cefixime is co-administered with oral anticoagulants (e.g., Warfarin derivatives), regulatory reports note a prolongation of the prothrombin time (INR), suggesting a documented effect on coagulation parameters.

Interacting Substance	Official Interaction Pattern
Probenecid	Increases Cefixime plasma concentration due to reduced renal clearance.
Oral Anticoagulants	Risk of prolonged Prothrombin Time (INR).
Polyvalent Cations (e.g., Iron, Antacids)	Timing separation is required; cations reduce Ofloxacin absorption, if present in the formulation.

If the Alcef-O formulation contains Ofloxacin, this component may lead to increased exposure of CYP1A2 substrates (e.g., Theophylline) due to metabolic inhibition. Co-administration of the Ofloxacin component with products containing polyvalent cations (such as certain antacids or mineral supplements) must be separated by time, as these substances interfere with drug absorption, resulting in reduced Ofloxacin exposure. The risk of coagulation effects is identified as potentially greater in patients with renal or hepatic impairment when Cefixime is administered.

Alcef-O acts through two distinct mechanistic domains to exert antibacterial effects.

Disruption of Bacterial Cell Wall Synthesis

Cefixime, a third-generation cephalosporin, engages mechanisms involving enzyme-mediated signaling by binding covalently to specific proteins on the bacterial membrane called penicillin-binding proteins (PBPs). This interaction is structurally selective and serves to inhibit the transpeptidation step necessary for synthesizing the peptidoglycan layer, a crucial component of the bacterial cell wall. The resulting physiological consequence is the osmotic instability and eventual rupture (lysis) of the bacterial cell, leading to the reduction of the viable bacterial population.

Inhibition of DNA Replication and Repair

Ofloxacin, a fluoroquinolone, acts by inhibiting two essential bacterial type II topoisomerase enzymes: DNA gyrase and topoisomerase IV. Inhibition of these targets prevents the enzymes from correctly managing the supercoiling, cleavage, and re-ligation of bacterial DNA, which is required for replication, transcription, and repair. The resulting intracellular cascade suppresses bacterial growth and proliferation, thereby leading to the cessation of replication in susceptible bacterial strains.

Official Administration Guidelines

Alcef-O (Cefixime) is approved exclusively for oral administration and is available as capsules, tablets, chewable tablets, and a powder for oral suspension. The standard administration principle requires the medicine to be taken without regard to food.

---

Dosing and Frequency

The typical adult regimen is 400 mg once daily or, alternatively, in two divided doses of 200 mg every 12 hours. For specific infections, such as uncomplicated gonorrhea, the labeled instruction is a single 400 mg oral dose. Pediatric patients (six months and older) are dosed based on weight at 8 mg/kg/day, which may be given once daily or split into two doses, up to the maximum adult dosage.

---

Special Instructions and Duration

Dosage adjustments are mandated for adults with renal impairment where creatinine clearance is significantly reduced. This requires a calculated dose decrease to ensure correct systemic exposure. When treating infections caused by Streptococcus pyogenes, the therapy must be maintained for a minimum of 10 days to complete the prescribed course. The oral suspension requires careful preparation, including shaking well before use and measuring the dose with a calibrated device. Furthermore, the tablet or capsule should not be used in place of the oral suspension for all indications, as they are not bioequivalent.

Alcef-O: Recent Clinical Evidence

The information below is a summary of the types of research and studies conducted on Alcef-O (Cefixime). It describes what researchers examined and what they monitored, but it does not provide any medical advice, clinical recommendations, or personal predictions about individual response. Research findings describe group patterns, not personal outcomes.

---

Evidence for use in Uncomplicated Urinary Tract Infections (UTI)

Research exploring Alcef-O for Uncomplicated Urinary Tract Infections (UTI) has primarily relied on Randomized Controlled Trials (RCTs). This medication was studied in research exploring how symptoms changed over time, often compared against specific, pre-determined treatments. Researchers monitored outcomes related to symptom resolution and the rate of microbiological clearance (lab confirmation of bacteria clearance from urine). These studies typically monitored adult women with acute, uncomplicated UTI, but evidence was also examined in pediatric patients. Limited information for long-term outcomes is available to characterize whether infections are likely to reappear, meaning long-term effects are not fully established.

---

Evidence for use in Respiratory Tract Infections

The evidence base for Alcef-O in respiratory conditions encompasses studies for specific conditions, such as acute exacerbations of chronic bronchitis and infections of the throat and ear.

Studies for Ear and Throat Infections (Otitis Media, Pharyngitis)

Studies monitored Alcef-O in individuals with acute otitis media (middle ear infection) and those with pharyngitis and tonsillitis (strep throat). These trials tracked whether patient-reported discomfort reached a defined resolution point (clinical response) and whether the specific bacteria were eliminated. Research describes the measured short-term changes in both symptoms and bacterial clearance rates. Comparative evidence is lacking to fully establish the potential for preventing certain rare, long-term complications of strep throat compared to the traditional 10-day standard therapy.

---

Evidence for use in Uncomplicated Gonorrhea

Alcef-O was evaluated in adults with uncomplicated gonorrhea, using research that assessed single-dose oral regimens. Studies monitored microbiological cure (lab confirmation of pathogen clearance). Studies reported patterns where microbiological clearance was observed in the treated populations. However, the evidence base faces a challenge from ongoing changes in bacterial resistance, and findings were mixed regarding the clearance rates for some sites, such as the throat.

---

Long-term Studies and Follow-up Durability

Most studies monitored outcomes for short-term and intermediate periods, meaning that follow-up durations were limited when trying to understand extended outcomes. There is limited information for long-term outcomes across all indications, such as the durability of the microbiological response or the frequency of infection recurrence over many months.

---

Evidence in Specific Patient Populations

Research has evaluated the use of the medication in children for conditions such as middle ear infections and strep throat. However, data for certain groups, such as infants under six months old, remain insufficient. Data for older adults with complex health conditions are also insufficient, meaning research results apply only to the populations studied.

---

Research Gaps and What Remains Uncertain

Key limitations in the evidence base include:

• Antibiotic Resistance: Evidence is limited regarding the use of this medication against currently resistant strains, which introduces uncertainty in regions where resistance is prevalent.
• Subgroup Findings: Comparative evidence is lacking for specific patient subgroups (such as very young infants or those with multiple chronic illnesses).
• Long-Term Data: Research is ongoing to assess long-term effects, such as the true rate of infection recurrence months after treatment.

Common questions about Alcef-O (FAQ)

Q: What is Alcef-O used for?

Alcef-O (Tofisopam) is typically prescribed to manage anxiety disorders and related symptoms. It is classified as an anxiolytic (anti-anxiety) medication. Dosing and regimen should be strictly followed as prescribed by a healthcare provider. The onset of action may vary among individuals; it is important to continue use as directed by the prescriber.

Q: How should I store Alcef-O?

For safe storage, the medication should be kept out of reach of children and stored at room temperature, protected from excess heat and moisture. It is advised to safely dispose of any medication past its expiration date, as quality and safety cannot be assured.

Q: Can I drink alcohol while taking Alcef-O?

The product information generally advises against the consumption of alcohol while taking Alcef-O. This combination may increase the risk of side effects like excessive sedation and impairment, and should be discussed with a doctor. It is essential to follow the specific advice of a healthcare professional regarding alcohol consumption.

How to Store and Dispose of Alcef-O?

The storage and disposal of Alcef-O (Cefixime) must strictly follow regulatory guidelines to maintain potency and ensure safety.

Storage Requirements

Condition	Requirement
Temperature	Store the dry product at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), not exceeding 30 C.
Environment	Keep the container tightly closed and protect the medicine from heat, moisture, and direct light. Do not freeze.
Child Safety	The medication must be kept out of the reach of children and pets.

---

Stability and Disposal

Stability: The reconstituted liquid suspension is stable for 14 days and must be discarded after this time, even if refrigerated.

Disposal: Unused or expired medication must not be flushed down the toilet. Dispose of the product according to local regulatory guidelines for pharmaceutical waste, often by discarding it in household trash after taking steps to prevent access.